好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Outcomes and prognostic factors in myelopathies
Multiple Sclerosis
P12 - Poster Session 12 (5:30 PM-6:30 PM)
12-005
To compare functional outcomes in inflammatory myelopathies (IM) and vascular myelopathies (VM) and determine prognostic factors.
IM and VM may present with similar clinical profiles but involve different pathophysiology mechanisms that can lead to different functional outcomes.
In this retrospective observational study including IM and VM subjects followed at the Johns Hopkins Myelitis Myelopathy Center (JHMMC), between 2010 and 2020, the modified Rankin scale (mRS) and the American Spinal Injury Association Impairment (ASIA) scale were evaluated at presentation and at the 2 subsequent follow up visits and compared between groups. Predictors of disability at follow up were identified by using logistic regression considering clinical, neuroimaging and CSF profiles at initial presentation.
One hundred forty-five IM and 75 VM (38 strokes and 37 AVF) patients were included. As compared to IM, the VM group had worst mRS scores and ASIA scores (more subjects with type A and B injury) at initial presentation and at follow-up evaluations (p <0.05 for all comparisons). At presentation, stroke-VM had worse mRS than the AVF-VM (p <0.05). However, this difference was not sustained at follow up. Similarly, stroke-VM had worse ASIA scores than AVF-VM at onset (p <0.05) but there was no significant difference at follow-up. Factors associated with worse prognosis (mRS>3 at follow up) included presence of longitudinally extensive lesions (>3 spinal levels) on initial MRI [OR 2.8 (CI 1.31-6.0)], rapid progression of initial symptoms (<48 hours to nadir) [OR 3.85 (CI 1.42-10.4)] for cases of VM and pleocytosis with WBC > 50 in CSF [OR 3.3 (CI 1.13-9.58)] for IM cases.
VM lead to worse functional outcomes compared to IM. Worse disability was predicted by presence of more extensive lesions, rapid progression of symptoms and CSF pleocytosis. Understanding the differences in prognosis in different types of myelopathies is important to appropriately counsel patients.
Authors/Disclosures
Maria A. Garcia-Dominguez, MD (UMass Memorial Medical Center)
PRESENTER 		Dr. Garcia-Dominguez has nothing to disclose.
Paula Barreras, MD (Cedars-Sinai Medical Center) Dr. Barreras has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Barreras has received research support from Foundation for Sarcoidosis Research. The institution of Dr. Barreras has received research support from 好色先生.
Carlos A. Pardo-Villamizar, MD (Johns Hopkins U, Med Dept of Neurology) The institution of Dr. Pardo-Villamizar has received research support from National Institutes of Health. The institution of Dr. Pardo-Villamizar has received research support from Bart McLean Fund for Neuroimmunology Research .